Citius Oncology, Inc. (CTOR)vsZoetis Inc (ZTS)
CTOR
Citius Oncology, Inc.
$0.78
-2.00%
HEALTHCARE · Cap: $72.48M
ZTS
Zoetis Inc
$79.44
-0.10%
HEALTHCARE · Cap: $33.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 169751% more annual revenue ($9.53B vs $5.61M). ZTS leads profitability with a 28.0% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 66/100 (B-).
CTOR
Avoid21
out of 100
Grade: F
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CTOR.
Margin of Safety
+11.8%
Fair Value
$145.86
Current Price
$79.44
$66.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Trading at 10.1x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CTOR
The strongest argument for CTOR centers on Debt/Equity, Price/Book.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : CTOR
The primary concerns for CTOR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
CTOR carries more volatility with a beta of 3.57 — expect wider price swings.
ZTS is growing revenue faster at 2.9% — sustainability is the question.
ZTS generates stronger free cash flow (291M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ZTS scores higher overall (66/100 vs 21/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Citius Oncology, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies tailored for underserved patient populations. With a robust pipeline of proprietary technologies, Citius aims to enhance treatment efficacy and safety across various cancer indications. The company is strategically advancing its promising drug candidates through pivotal clinical trials and regulatory processes, leveraging partnerships and rigorous clinical research standards to optimize patient outcomes and address critical needs in the oncology sector.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?